Self-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing cabazitaxel as a drug delivery system

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 2307-2317

  Song, Yanzhi ^a   Tian, Qingjing ^a   Huang, Zhenjun ^a   Fan, Di ^a   She, Zhennan ^a   Liu, Xinrong ^a   Cheng, Xiaobo ^a   Yu, Bin ^b   Deng, Yihui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Liaoning Medical Device Test Institute   (China)

Author keywords

Cabazitaxel; Cancer therapy; Cholesterol; Micelles; Pluronic F68; Synthesis

Indexed keywords

CABAZITAXEL; CHOLESTEROL PLUS POLOXAMER; COPOLYMER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHOLESTEROL; EMULSION; MACROGOL DERIVATIVE; MICELLE; NANOCAPSULE; PEO-PPO-PEO; PROPANEDIOL DERIVATIVE; SURFACTANT; TAXOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY ASSAY; DELAYED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MICELLE; MOLECULAR STABILITY; MOUSE; NONHUMAN; PARTICLE SIZE; STRUCTURE ANALYSIS; SUSTAINED DRUG RELEASE; ANIMAL; APOPTOSIS; CARCINOMA, EHRLICH TUMOR; CHEMISTRY; CRYSTALLIZATION; DIFFUSION; DRUG EFFECTS; DRUG POTENTIATION; EMULSION; PATHOLOGY; PROCEDURES; SYNTHESIS; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, EHRLICH TUMOR; CELL LINE, TUMOR; CHOLESTEROL; CRYSTALLIZATION; DIFFUSION; DRUG SYNERGISM; EMULSIONS; MICE; MICELLES; NANOCAPSULES; POLYETHYLENE GLYCOLS; PROPYLENE GLYCOLS; SURFACE-ACTIVE AGENTS; TAXOIDS; TREATMENT OUTCOME;

EID: 84900431637     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S61220     Document Type: Article

References (41)

1. Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. J Pharm Sci. 2003;92(7):1343-1355.
2. Wei Z, Hao J, Yuan S, et al. Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: formulation, optimization and in vitro characterization. Int J Pharm. 2009;376(1):176-185.
3. Sahu A, Kasoju N, Goswami P, Bora U. Encapsulation of curcumin in pluronic block copolymer micelles for drug delivery applications.J Biomater Appl. 2011;25(6):619-639.
4. Chen L, Sha X, Jiang X, Chen Y, Ren Q, Fang X. Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation. Int J Nanomedicine. 2013;8:73-84.
5. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release. 2002;82(2):189-212.
6. Oh KT, Bronich TK, Kabanov AV. Micellar formulations for drug delivery based on mixtures of hydrophobic and hydrophilic Pluronic® block copolymers. J Control Release. 2004;94(2):411-422.
7. Zhou Q, Zhang Z, Chen T, Guo X, Zhou S. Preparation and characterization of thermosensitive pluronic F127-b-poly (ε-caprolactone) mixed micelles. Colloids Surf B Biointerfaces. 2011;86(1):45-57.
8. Armstrong A, Brewer J, Newman C, et al. SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: a phase II window study. J Clin Oncol. 2006;24(Suppl 18):4080
9. Valle JW, Armstrong A, Newman C, et al. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Investig New Drugs. 2011;29(5):1029-1037.
10. Alakhova DY, Zhao Y, Li S, Kabanov AV. Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia. PLoS One. 2013;8(8): e72238.
11. Grindel JM, Jaworski T, Piraner O, Emanuele RM, Balasubramanian M. Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans. J Pharm Sci. 2002;91(9):1936-1947.
12. Zhao L, Du J, Duan Y, et al. Curcumin loaded mixed micelles composed of Pluronic P123 and F68: preparation, optimization and in vitro characterization. Colloids Surf B Biointerfaces. 2012;97:101-108.
13. Cha M-H, Choi J, Choi BG, et al. Synthesis and characterization of novel thermo-responsive F68 block copolymers with cell-adhesive RGD peptide. J Colloid Interface Sci. 2011;360(1):78-85.
14. Boyd N, Connelly P, Lynch H, et al. Plasma lipids, lipoproteins, and familial breast cancer. Cancer Epidemiol Biomarkers Prev. 1995;4(2): 117-122.
15. Danilo C, Frank PG. Cholesterol and breast cancer development. Curr Opin Pharmacol. 2012;12(6):677-682.
16. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J Cell Biochem. 2004;91(1):54-69.
17. Dessì S, Batetta B, Pulisci D, et al. Cholesterol content in tumor tissues is inversely associated with high-density lipoprotein cholesterol in serum in patients with gastrointestinal cancer. Cancer. 1994;73(2):253-258.
18. Xu L, Betker J, Yin H, Anchordoquy TJ. Ligands located within a cholesterol domain enhance gene delivery to the target tissue. J Control Release. 2012;160(1):57-63.
19. Zhang Y, Bradshaw-Pierce EL, DeLille A, Gustafson DL, Anchordoquy TJ. In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: effects on biodistribution and tumor accumulation. J Pharm Sci. 2008;97(1):237-250.
20. Xu L, Anchordoquy TJ. Effect of cholesterol nanodomains on the targeting of lipid-based gene delivery in cultured cells. Mol Pharm. 2010;7(4):1311-1317.
21. Lee AL, Wang Y, Pervaiz S, Fan W, Yang YY. Synergistic anticancer effects achieved by co-delivery of TRAIL and paclitaxel using cationic polymeric micelles. Macromol Biosci. 2011;11(2):296-307.
22. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15(2):723-730.
23. Pivot X, Koralewski P, Hidalgo J, et al. A multicenter phase II study of XRP6258 administered as a 1-h iv infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19(9): 1547-1552.
24. Oudard S. TROPIC: phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. 2011;7(4):497-506.
25. Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2011;5:117.
26. Xu H, Deng Y, Chen D, Hong W, Lu Y, Dong X. Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives. J Control Release. 2008;130(3):238-245.
27. Song H, Geng H, Ruan J, et al. Development of polysorbate 80/phospholipid mixed micellar formation for docetaxel and assessment of its in vivo distribution in animal models. Nanoscale Res Lett. 2011;6(1):1-12.
28. Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids and Surfaces B: Biointerfaces. 2011;85(2):262-269.
29. Ananthapadmanabhan K, Goddard E, Turro N, Kuo P. Fluorescence probes for critical micelle concentration. Langmuir. 1985;1(3): 352-355.
30. Kohori F, Yokoyama M, Sakai K, Okano T. Process design for efficient and controlled drug incorporation into polymeric micelle carrier systems. J Control Release. 2002;78(1):155-163.
31. Zhang X, Jackson JK, Burt HM. Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharm. 1996;132(1): 195-206.
32. Sant VP, Smith D, Leroux J-C. Novel pH-sensitive supramolecular assemblies for oral delivery of poorly water soluble drugs: preparation and characterization. J Control Release. 2004;97(2):301-312.
33. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010;188(6):759-768.
34. Guo X, Shi C, Wang J, Di S, Zhou S. pH-triggered intracellular release from actively targeting polymer micelles. Biomaterials. 2013;34(18): 4544-4554.
35. Kim K-S, Park S-J. Effect of porous silica on sustained release behaviors of pH sensitive pluronic F127/poly (acrylic acid) hydrogels containing tulobuterol. Colloids Surf B Biointerfaces. 2010;80(2): 240-246.
36. Gao Z-G, Fain HD, Rapoport N. Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J Control Release. 2005;102(1):203-222.
37. Lee AL, Venkataraman S, Sirat S, Gao S, Hedrick JL, Yang YY. The use of cholesterol-containing biodegradable block copolymers to exploit hydrophobic interactions for the delivery of anticancer drugs. Biomaterials. 2012;33(6):1921-1928.
38. Simoes S, Tapadas J, Marques C, Cruz M, Martins M, Cevc G. Permeabilisation and solubilisation of soybean phosphatidylcholine bilayer vesicles, as membrane models, by polysorbate, Tween 80. Eur J Pharm Sci. 2005;26(3):307-317.
39. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006;66(7):3351-3354.
40. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006;16(1):3-15.
41. Maeda H, Bharate G, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71(3):409-419.